CytRx completes patient dosing, follow-up in Lou Gehrig's disease trial

By Elaine Rigoli

Tampa, Fla., July 24 - CytRx Corp. announced that the final patients have completed dosing and follow-up with arimoclomol in the company's phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

The company said patients were evaluated while receiving either a placebo or one of three dose levels of CytRx's lead product candidate arimoclomol three times daily for 12 weeks and during a four-week follow-up period without drug.

The company said it will now evaluate and analyze the data and announce final results early in the fourth quarter of this year.

Ten clinical centers across the United States participated in CytRx's double-blind, placebo-controlled phase 2a trial. The primary endpoints of the phase 2a trial were safety and tolerability.

Subject to approval from the Food and Drug Administration, CytRx said it intends to start a phase 2b efficacy trial in the first half of 2007.

CytRx is a biopharmaceutical research and development company located in Los Angeles.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.